Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targacept CEO J. Donald DeBethizy - An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

DeBethizy discusses the firm’s unique origins, its work with AstraZeneca and what’s ahead for the Raleigh, N.C.-based company.

You may also be interested in...



Targacept CEO J. Donald DeBethizy – An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

DeBethizy discusses the firm’s deal with GlaxoSmithKline and what lies ahead for the Raleigh, N.C.-based company.

Targacept CEO J. Donald DeBethizy – An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

DeBethizy discusses the firm’s deal with GlaxoSmithKline and what lies ahead for the Raleigh, N.C.-based company.

AstraZeneca Licenses Nicotinic Alzheimer’s Treatment From Targacept

Firm aims to bring the tobacco spin-off’s developmental neuronal nicotinic receptor modulator TC-1734 to market for Alzheimer’s and other cognitive disorders.

Topics

UsernamePublicRestriction

Register

PS067431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel